Specifically differentiated T cell subset promotes tumor immunity over fatal immunity

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Allogeneic T cell transfer is vital for treating hematological malignancies, inducing graft-versus-leukemia (GVL) reactivity against cancer cells.
• Graft-versus-host disease (GVHD), an attack on host tissues by donor T cells, poses a significant, often fatal, risk, limiting treatment efficacy.
• Achieving a complete separation between GVL and GVHD remains a critical challenge in immunotherapy.

Purpose of the Study:

• To investigate a specific population of T cells, interleukin-9 (IL-9)-producing T cells activated via the ST2-IL-33 pathway (T9_IL-33 cells).
• To determine if T9_IL-33 cells can enhance GVL reactivity while simultaneously mitigating GVHD.
• To explore the underlying mechanisms responsible for the potential separation of GVL and GVHD.

Main Methods:

• Utilized mouse and human models to study T cell populations.
• Activated T cells via the ST2-IL-33 pathway to generate T9_IL-33 cells.
• Compared the GVL and GVHD effects of T9_IL-33 cells against T9, T1, and unmanipulated T cells, analyzing amphiregulin and CD8α expression.

Main Results:

• T9_IL-33 cells demonstrated increased GVL activity compared to other T cell types.
• T9_IL-33 cells significantly reduced GVHD, offering protection from fatal immune responses.
• Amphiregulin expression mediated protection from fatal immunity, while CD8α expression augmented antileukemic activity.

Conclusions:

• Adoptive transfer of allogeneic T9_IL-33 cells represents a novel strategy for separating GVL from GVHD.
• This approach holds significant potential for improving the safety and efficacy of immunotherapy for high-risk hematological malignancies.
• Targeting the ST2-IL-33 pathway offers a promising avenue for developing next-generation cancer immunotherapies.